Steven Reed - 14 Feb 2023 Form 4 Insider Report for Bellevue Life Sciences Acquisition Corp. (OSRH)

Role: Director
Signature: /s/ Steven Reed
Issuer symbol: OSRH
Transactions as of: 14 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 16 Feb 2023, 19:05:41 UTC
Previous filing: 09 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLAC	Common Stock	Award	$0	+20,000		$0.000000	20,000	14 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLAC	Warrant for Common Stock	Award	$0	+20,000		$0.000000	20,000	14 Feb 2023	Common Stock	20,000	$11.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the shares transferred by Bellevue Global Life Sciences Investors LLC (the "Sponsor"), the sponsor of the Issuer, to Mr. Reed for his board service.
F2	Represents the warrants to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Reed for his service as Chairman of the Board of Directors. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments.

Content

Represents the shares transferred by Bellevue Global Life Sciences Investors LLC (the "Sponsor"), the sponsor of the Issuer, to Mr. Reed for his board service.

Represents the warrants to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Reed for his service as Chairman of the Board of Directors. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments.